Current COVAX efforts are too slow – will cost 28 trillion in lost output
Katherine Aguirre,, 6-21-2021, researcher at the Igarapé Institute. Gordon LaForge is a senior researcher at Princeton University and a lecturer at Arizona State University’s Thunderbird School of Global Management. Robert Muggah is a principal at the SecDev Group, a co-founder of the Igarapé Institute, and the author, with Ian Goldin, of Terra Incognita: 100 Maps to Survive the Next 100 Years. Twitter: @robmuggah Anne-Marie Slaughter is the CEO of New America https://foreignpolicy.com/2021/06/21/global-vaccination-covax-gavi-covid-19-pandemic-impact-hubs-public-private-funding-united-nations/, "Three Years Is Too Long to Wait for a Global Vaccine Rollout," Foreign Policy (ermo/sms, Acc:6-20-2022)
At first sight, the global vaccination rollout is mesmerizing. At least 2.4 billion people have already received at least one dose. But scrape a little deeper and the unevenness of vaccine distribution loses its luster. Just 480 million people have been fully vaccinated or 6.2 percent of the global population. What’s more, well over half of all administered doses have been injected into the arms of citizens from just two countries: the United States and China.
Following their summit in Cornwall, England, last week, the leaders of the G-7 nations committed to donating an additional 1 billion COVID-19 vaccines to poorer countries in 2021 and 2022. The Biden administration said 500 million of those doses would be provided by the United States, mostly through COVID-19 Vaccines Global Access (COVAX), a global vaccine facility managed by the Global Vaccine Alliance (Gavi) and the Coalition for Epidemic Preparedness Innovations. China is likewise distributing jabs to advance foreign-policy goals, having so far exported more than 250 million doses to other countries.
Notwithstanding the surge in vaccine diplomacy, far more investment is needed. Less than 1 percent of the billions of vaccine doses administered to date have gone to low-income countries. At the current rate of distribution, it will take until 2024 before all countries have sufficient supplies to vaccinate their populations. It is not just vaccine nationalism and supply chain disruptions that are slowing vaccination in poorer countries, but also financial constraints. To attain even the modest goal of vaccinating 20 percent of the people in 92 low-income countries by the end of the year, COVAX said it needs an additional $2.8 billion.
The delay is dangerous and costly for all nations. Recurrent outbreaks will prolong the global economic slowdown, which has already cost the world $28 trillion in lost output. If, by this summer, wealthier nations are fully vaccinated yet developing nations remain unvaccinated, global economic losses could add an additional $9 trillion to the bill. And the longer more contagious and lethal variants are allowed to incubate and spread, the greater the risk a vaccine-resistant strain emerges. As U.S. President Joe Biden has said, “We will ultimately not be safe until the world is safe.”
An urgent, all-hands-on-deck effort is needed to fund COVAX and Gavi in particular. So far, the focus has been on what governments can do. Mapping the funding network for Gavi and COVAX reveals two intriguing features of the current financing environment. First, governments have provided the lion’s share of financial support. Of the $9.5 billion pledged, $8.8 billion is from national governments. Second, although the remaining funding only makes up a small share, it comes from a surprisingly diverse array of organizations, including philanthropic foundations, corporations like Visa and Google, and even civil society groups like the charitable video game festival Gamers Without Borders.